Sector News

Rasna Therapeutics goes public with reverse merger deal

August 17, 2016
Life sciences

Leukemia and lymphoma biotech Rasna Therapeutics has pulled off a reverse merger with an unlikely partner as it plans to list on the OTC Markets under the symbol “ATVM.”

The reverse merger, which more quickly propels the formerly private biotech into the public sphere, has been done through Active With Me–a Canadian company that offers online information on activity-based travel to travelers.

The two are strange bedfellows, given that U.K.-based Rasna Therapeutics works on cancer drugs, but the deal has now been finalized and allows the biotech to trade its shares publicly, with the combined company to be named Rasna Therapeutics.

The early-stage biotech is currently working on modulating the molecular targets LSD1 and NPM1, which are implicated in the progression of both leukemia and lymphoma.

“Becoming a public company is a key element of our growth strategy, and the completion of this reverse merger is a significant accomplishment for Rasna Therapeutics,” said James Tripp, acting CEO of Rasna.

“We believe that this breakthrough program may have significant benefits across all forms of leukemia. Our NPM1 program targets the sub-set of acute myeloid leukemia patients with the NPM1 mutation and may also benefit the general AML population. We are aiming to have a lead candidate identified by 2017.”

Rasna was formed in 2013 by biotech entrepreneur Gabriele Cerrone together with Dr. Roberto Pellicciari, a medicinal chemist and the scientific founder of Intercept Pharmaceuticals ($ICPT), and Dr. Brunangelo Falini, a physician and hematologist.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.